Vera reports TRUTAKNA kidney trial data
Vera Therapeutics (NASDAQ:VERA) reported final Phase 3 ORIGIN 3 results showing TRUTAKNA (atacicept-vymj) stabilized kidney function and reduced disease progression over two years in adults with primary IgA nephropathy at risk of progression.























-640x360.webp&w=3840&q=75)